{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intravitreal+injection+of+Aflibercept",
    "query": {
      "intervention": "Intravitreal injection of Aflibercept"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 159,
    "total_pages": 16,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intravitreal+injection+of+Aflibercept&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-25T02:41:56.770Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03468296",
      "title": "Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Intravitreal Aflibercept Injection 2mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tennessee Retina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2018-04",
      "completion_date": "2019-07",
      "has_results": false,
      "last_update_posted_date": "2018-04-20",
      "last_synced_at": "2026-09-25T02:41:56.770Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03468296"
    },
    {
      "nct_id": "NCT03577899",
      "title": "Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "0.5 mg Conbercept Intravitreal Injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "1.0 mg Conbercept Intravitreal Injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "2.0 mg Aflibercept Intravitreal Injection",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Chengdu Kanghong Biotech Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 1157,
      "start_date": "2018-09-25",
      "completion_date": "2021-05-19",
      "has_results": false,
      "last_update_posted_date": "2021-06-24",
      "last_synced_at": "2026-09-25T02:41:56.770Z",
      "location_count": 63,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03577899"
    },
    {
      "nct_id": "NCT02418754",
      "title": "Study of Intravitreal REGN2176-3 in Participants With Neovascular (\"Wet\") Age-Related Macular Degeneration (AMD)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "REGN2176-3",
          "type": "DRUG"
        },
        {
          "name": "Intravitreal Aflibercept Injection (IAI)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 505,
      "start_date": "2015-05-05",
      "completion_date": "2017-04-03",
      "has_results": true,
      "last_update_posted_date": "2020-10-26",
      "last_synced_at": "2026-09-25T02:41:56.770Z",
      "location_count": 75,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 72 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02418754"
    },
    {
      "nct_id": "NCT01578720",
      "title": "Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Choroidal Neovascularization",
        "Presumed Ocular Histoplasmosis"
      ],
      "interventions": [
        {
          "name": "EYLEA (Aflibercept) intravitreal injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Retina Research Institute, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2012-06",
      "completion_date": "2015-03",
      "has_results": false,
      "last_update_posted_date": "2018-08-29",
      "last_synced_at": "2026-09-25T02:41:56.770Z",
      "location_count": 3,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01578720"
    },
    {
      "nct_id": "NCT01710332",
      "title": "The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Central Serous Chorioretinopathy"
      ],
      "interventions": [
        {
          "name": "Intravitreal Aflibercept Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wills Eye",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 12,
      "start_date": "2012-10",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2017-06-16",
      "last_synced_at": "2026-09-25T02:41:56.770Z",
      "location_count": 2,
      "location_summary": "Huntingdon Valley, Pennsylvania • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Huntingdon Valley",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01710332"
    },
    {
      "nct_id": "NCT01495221",
      "title": "To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "AMD (With Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy)"
      ],
      "interventions": [
        {
          "name": "Alfilbercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vitreous -Retina- Macula Consultants of New York",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2011-12",
      "completion_date": "2013-03",
      "has_results": true,
      "last_update_posted_date": "2018-09-07",
      "last_synced_at": "2026-09-25T02:41:56.770Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01495221"
    },
    {
      "nct_id": "NCT02307682",
      "title": "Efficacy and Safety of RTH258 Versus Aflibercept - Study 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration",
        "Choroidal Neovascularization"
      ],
      "interventions": [
        {
          "name": "Brolucizumab ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept ophthalmic solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 1775,
      "start_date": "2014-12-08",
      "completion_date": "2018-03-28",
      "has_results": true,
      "last_update_posted_date": "2025-01-16",
      "last_synced_at": "2026-09-25T02:41:56.770Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02307682"
    },
    {
      "nct_id": "NCT01363440",
      "title": "Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)",
          "type": "DRUG"
        },
        {
          "name": "Macular Laser Photocoagulation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 466,
      "start_date": "2011-05",
      "completion_date": "2014-11",
      "has_results": true,
      "last_update_posted_date": "2016-05-30",
      "last_synced_at": "2026-09-25T02:41:56.770Z",
      "location_count": 51,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 48 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01363440"
    },
    {
      "nct_id": "NCT01617148",
      "title": "Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Exudative Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rishi Singh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2012-06",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2018-07-26",
      "last_synced_at": "2026-09-25T02:41:56.770Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01617148"
    },
    {
      "nct_id": "NCT03249740",
      "title": "A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "GB-102",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Graybug Vision",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2017-08-29",
      "completion_date": "2019-01-16",
      "has_results": false,
      "last_update_posted_date": "2019-12-20",
      "last_synced_at": "2026-09-25T02:41:56.770Z",
      "location_count": 8,
      "location_summary": "Gilbert, Arizona • Beverly Hills, California • Indianapolis, Indiana + 5 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Lynbrook",
          "state": "New York"
        },
        {
          "city": "Abilene",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03249740"
    }
  ]
}